BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26755530)

  • 1. The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer.
    Choi SY; Xue H; Wu R; Fazli L; Lin D; Collins CC; Gleave ME; Gout PW; Wang Y
    Clin Cancer Res; 2016 Jun; 22(11):2721-33. PubMed ID: 26755530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.
    Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
    Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Luk IS; Shrestha R; Xue H; Wang Y; Zhang F; Lin D; Haegert A; Wu R; Dong X; Collins CC; Zoubeidi A; Gleave ME; Gout PW; Wang Y
    Clin Cancer Res; 2017 Mar; 23(6):1542-1551. PubMed ID: 27663589
    [No Abstract]   [Full Text] [Related]  

  • 4. [MCT4 reduces glucose metabolism and promotes apoptosis of prostate cancer cells].
    Hong P; Wang PC
    Zhonghua Nan Ke Xue; 2018 Nov; 24(11):974-978. PubMed ID: 32212469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgens enhance the glycolytic metabolism and lactate export in prostate cancer cells by modulating the expression of GLUT1, GLUT3, PFK, LDH and MCT4 genes.
    Vaz CV; Marques R; Alves MG; Oliveira PF; Cavaco JE; Maia CJ; Socorro S
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):5-16. PubMed ID: 26048031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis.
    Kim HK; Lee I; Bang H; Kim HC; Lee WY; Yun SH; Lee J; Lee SJ; Park YS; Kim KM; Kang WK
    Mol Cancer Ther; 2018 Apr; 17(4):838-848. PubMed ID: 29483215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional screening identifies MCT4 as a key regulator of breast cancer cell metabolism and survival.
    Baenke F; Dubuis S; Brault C; Weigelt B; Dankworth B; Griffiths B; Jiang M; Mackay A; Saunders B; Spencer-Dene B; Ros S; Stamp G; Reis-Filho JS; Howell M; Zamboni N; Schulze A
    J Pathol; 2015 Oct; 237(2):152-65. PubMed ID: 25965974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid-oligonucleotide conjugates improve cellular uptake and efficiency of TCTP-antisense in castration-resistant prostate cancer.
    Karaki S; Benizri S; Mejías R; Baylot V; Branger N; Nguyen T; Vialet B; Oumzil K; Barthélémy P; Rocchi P
    J Control Release; 2017 Jul; 258():1-9. PubMed ID: 28472637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer.
    Choi SYC; Ettinger SL; Lin D; Xue H; Ci X; Nabavi N; Bell RH; Mo F; Gout PW; Fleshner NE; Gleave ME; Collins CC; Wang Y
    Cancer Med; 2018 Jul; 7(7):3385-3392. PubMed ID: 29905005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer.
    Todenhöfer T; Seiler R; Stewart C; Moskalev I; Gao J; Ladhar S; Kamjabi A; Al Nakouzi N; Hayashi T; Choi S; Wang Y; Frees S; Daugaard M; Oo HZ; Fisel P; Schwab M; Schaeffeler E; Douglas J; Hennenlotter J; Bedke J; Gibb EA; Fazli L; Stenzl A; Black PC
    Mol Cancer Ther; 2018 Dec; 17(12):2746-2755. PubMed ID: 30262589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis.
    Lee JY; Lee I; Chang WJ; Ahn SM; Lim SH; Kim HS; Yoo KH; Jung KS; Song HN; Cho JH; Kim SY; Kim KM; Lee S; Kim ST; Park SH; Lee J; Park JO; Park YS; Lim HY; Kang WK
    Oncotarget; 2016 Jul; 7(28):43492-43503. PubMed ID: 27224918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V; Menon M; Thamilselvan S
    Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen-responsive and nonresponsive prostate cancer cells present a distinct glycolytic metabolism profile.
    Vaz CV; Alves MG; Marques R; Moreira PI; Oliveira PF; Maia CJ; Socorro S
    Int J Biochem Cell Biol; 2012 Nov; 44(11):2077-84. PubMed ID: 22964025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MCT4 promotes cell proliferation and invasion of castration-resistant prostate cancer PC-3 cell line.
    Sun Q; Hu LL; Fu Q
    EXCLI J; 2019; 18():187-194. PubMed ID: 31217781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231.
    Gallagher SM; Castorino JJ; Wang D; Philp NJ
    Cancer Res; 2007 May; 67(9):4182-9. PubMed ID: 17483329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4.
    Hong CS; Graham NA; Gu W; Espindola Camacho C; Mah V; Maresh EL; Alavi M; Bagryanova L; Krotee PAL; Gardner BK; Behbahan IS; Horvath S; Chia D; Mellinghoff IK; Hurvitz SA; Dubinett SM; Critchlow SE; Kurdistani SK; Goodglick L; Braas D; Graeber TG; Christofk HR
    Cell Rep; 2016 Feb; 14(7):1590-1601. PubMed ID: 26876179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TP53INP1 as new therapeutic target in castration-resistant prostate cancer.
    Giusiano S; Baylot V; Andrieu C; Fazli L; Gleave M; Iovanna JL; Taranger-Charpin C; Garcia S; Rocchi P
    Prostate; 2012 Sep; 72(12):1286-94. PubMed ID: 22213058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration.
    Gao HJ; Zhao MC; Zhang YJ; Zhou DS; Xu L; Li GB; Chen MS; Liu J
    J Cancer Res Clin Oncol; 2015 Jul; 141(7):1151-62. PubMed ID: 25446815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of monocarboxylate transporter-4 depletes stem-like glioblastoma cells and inhibits HIF transcriptional response in a lactate-independent manner.
    Lim KS; Lim KJ; Price AC; Orr BA; Eberhart CG; Bar EE
    Oncogene; 2014 Aug; 33(35):4433-41. PubMed ID: 24077291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target.
    Gerlinger M; Santos CR; Spencer-Dene B; Martinez P; Endesfelder D; Burrell RA; Vetter M; Jiang M; Saunders RE; Kelly G; Dykema K; Rioux-Leclercq N; Stamp G; Patard JJ; Larkin J; Howell M; Swanton C
    J Pathol; 2012 Jun; 227(2):146-56. PubMed ID: 22362593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.